A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
CA 2310926 C · Owner: Janssen Pharmaceutica Inc. · Inventors: Pontecorvo, Michael; Parys, Wim Louis Julien
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Galantamine has be used in the treatment of a number of chronic diseases. Galantamine has been found to be safe and effective in the treatment of Alzheimer's disease. Neuropsychiatric disorders are often associated with Alzheimer's disease. It is demonstrated that galantamine is also effective in reducing or stabilizing the incidence of neuropsychiatric behaviour seen in Alzheimer's patients.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 27, 2000 and granted October 15, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 27, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 27, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.